Hypogonadism Clinical Trial
Official title:
Exercise and Testosterone Therapy in Elderly Men With Physical Frailty
Verified date | January 2018 |
Source | Washington University School of Medicine |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary aim of this study is to determine, in hypogonadal older men with physical frailty, whether exercise training combined with testosterone replacement therapy can improve skeletal muscle strength, and lean mass, to a greater degree than exercise training alone.
Status | Completed |
Enrollment | 25 |
Est. completion date | August 2009 |
Est. primary completion date | February 2009 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 65 Years and older |
Eligibility |
Inclusion Criteria: - Male, age 65 years and older - Total serum testosterone level < 350 ng/dl - Total Modified Physical Performance Test Score <28 Exclusion Criteria: - Inability to walk 50 feet independently - Current use of estrogen, progestin, or androgen containing compound - Diagnosis of dementia of severity sufficient to interfere with informed consent or compliance with the protocol, or a score of 11 or greater on the Short Blessed Test of Orientation, Memory and Concentration - Visual or hearing impairments that interfere with following directions - Cardiopulmonary disease (recent MI, unstable angina or CHF, etc.), neuromuscular impairments, or unstable medical condition that would contraindicate progressive resistance exercise training - History of prostate cancer or hormone dependent neoplasia - PSA level > 4 ng/ml - Serum liver transaminase levels of greater than 2 standard deviations above normal - Use of drugs for osteoporosis for less than 1 year - Current participation in a vigorous exercise or weight-training program more than once per week - History of sleep apnea requiring use of CPAP - Uncontrolled thyroid disease - Diagnosis of cancer within the past 5 years other than superficial skin cancer (squamous or basal cell) - hematocrit > 50% - AUA symptom score > 16. - History of alcohol or substance abuse - Presence of severe facial acne - Active symptoms of depression with GDS score > 5 and symptoms severe enough to cause >5% weight loss in previous 3 months or interfere with research assessments |
Country | Name | City | State |
---|---|---|---|
United States | Washington University School of Medicine | Saint Louis | Missouri |
Lead Sponsor | Collaborator |
---|---|
Washington University School of Medicine | Solvay Pharmaceuticals |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in Serum Prostate Specific Antigen (PSA) Level | Baseline and Six Months | ||
Other | Change in Hematocrit | Percentage of the volume of whole blood composed of Red Blood Cells | Baseline and Six Months | |
Other | Change in Serum Total Cholesterol Level | Baseline and Six Months | ||
Other | Change in Serum HDL Cholesterol Level | Baseline and Six Months | ||
Other | Change in Serum LDL Cholesterol Level | Baseline and Six Months | ||
Primary | Mean Change in Total Lean Body Mass | Total Lean Mass measured by Dual X-ray Absorptiometry (DXA) | Baseline and Six Months | |
Primary | Change in Skeletal Muscle Strength by 1-RM | One-repetition maximum strength for leg extension | Baseline and Six Months | |
Secondary | Change in Isokinetic Leg Extension Torque at 0 Deg/Sec | Leg Extension Torque measured with Cybex dynamometer at 0 deg/sec | Baseline and Six Months | |
Secondary | Change in Leg Extension Torque at 60 Deg/Sec | Leg Extension Torque measured with Cybex dynamometry at 60 deg/sec | Baseline and Six Months | |
Secondary | Change in Total Body Fat Mass | Total Body Fat Mass as measured by DXA | Baseline and Six Months | |
Secondary | Change in Femoral Bone Mineral Density (BMD) | Femoral Bone Mineral Density measured with Dual X-ray Absorptiometry (DXA) | Baseline and Six Months | |
Secondary | Change in Total Modified Physical Performance (mPPT) Score | The Modified Physical Performance Test (mPPT) is a direct observational test that assesses multiple dimensions of physical function (basic and complex activities of daily living [ADL]) with different levels of difficulty. The test consists of 9 performance tasks. The total score range is 0-36 (min-max), with higher scores indicating better performance. Sub-scores are assigned for each of 9 item tasks; sub-score range is 0-4 (min-max) with higher scores indicating better performance. The sub-scores are summed to compute the total score. | Baseline and Six Months | |
Secondary | Change in Serum Testosterone Level | Total Serum Testosterone Level (ng/mL) | Baseline and Six Months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03126656 -
Effects of Testosterone on Myocardial Repolarization
|
Phase 4 | |
Terminated |
NCT02419105 -
Effects of Transdermal Testosterone and/or Monthly Vitamin D on Fall Risk in Pre--frail Hypogonadal Seniors
|
Phase 3 | |
Withdrawn |
NCT02137265 -
Assessing the Efficacy of Clomiphene Citrate in Patients With Azoospermia and Hypoandrogenism
|
N/A | |
Completed |
NCT02222558 -
Oral Testosterone for the Treatment of Hypogonadism in Males
|
Phase 2 | |
Completed |
NCT02233751 -
Pharmacokinetic Study of Subcutaneous Testosterone Enanthate
|
Phase 1 | |
Completed |
NCT01887418 -
Pharmacokinetic Study of Testosterone Enanthate
|
Phase 1/Phase 2 | |
Terminated |
NCT01092858 -
NEBIDO in Symptomatic Late Onset Hypogonadism (SLOH)
|
Phase 4 | |
Completed |
NCT00624624 -
Follow-up of Serum Androgen Profile After Bariatric Surgery in Men With Obesity Related Hypogonadotropic Hypogonadism
|
N/A | |
Completed |
NCT00752869 -
Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement
|
Phase 4 | |
Completed |
NCT00613288 -
Testosterone and Lipolysis, Insulin Sensitivity and Protein Metabolism
|
N/A | |
Completed |
NCT00838838 -
Efficacy of Nebido on Bone Mineral Density (BMD) in Hypogonadal Paraplegic Patients With Confirmed Osteoporosis
|
N/A | |
Completed |
NCT00119483 -
Older Men and Testosterone
|
N/A | |
Completed |
NCT00004438 -
Leuprolide in Treating Adults With Hypogonadotropism
|
N/A | |
Withdrawn |
NCT00398034 -
Analgesic Efficacy of Testosterone Replacement in Hypogonadal Opioid-treated Chronic Pain Patients: A Pilot Study.
|
Phase 2 | |
Completed |
NCT02921386 -
The Effect of Various Amounts of Fat on PK of Oral Testosterone Undecanoate
|
Phase 2 | |
Completed |
NCT02937740 -
Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natestoâ„¢
|
Phase 4 | |
Completed |
NCT01717768 -
Oral Testosterone for the Treatment of Hypogonadism
|
Phase 2 | |
Terminated |
NCT01460654 -
Testosterone and Alendronate in Hypogonadal Men
|
Phase 2 | |
Completed |
NCT00998933 -
Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure
|
Phase 1 | |
Withdrawn |
NCT00710827 -
Nebido Versus Placebo in Elderly Men With Typical Symptoms of Late Onset Hypogonadism Over a Period of 54 Weeks
|
Phase 4 |